Dear Colleagues,
Sincerely,
Our society continues its preparations toward our fully
virtual 35th
Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020),
scheduled for Nov. 9–14, 2020. Please take note that the SITC 2020 meeting
registration fee has been waived for ALL SITC members. You can become a
member or renew your membership during the SITC 2020
online registration process.
Also, to accommodate for the COVID-19 impact on cancer
immunotherapy research this year, the late-breaking
abstract (LBA) submission period will be opened to everyone. SITC will
not require an LBA application to be submitted beforehand. Previously
submitted LBA applications will automatically be invited to submit a full LBA
during the LBA submission period, Sept. 8-22, 2020, at 5 p.m. PDT.
In addition to the intense preparations for the Annual
Meeting, the Society for Immunotherapy of Cancer continues to make progress on
its objectives for this year. Educating clinicians on all aspects of cancer
immunotherapy is one of our main objectives and directly serves the goal of
improving patient outcomes. This past month the Certificate in Cancer
Immunotherapy Program was launched, and is
being offered online via our society’s SITC Cancer
Immunotherapy connectED platform. The SITC certificate consists of eight learning modules all of which offer relevant
education credits (CME, CNE, CPE and MOC).
After successful completion of the modules, the SITC Graduate in Cancer
Immunotherapy (SITC-G) designation is granted and identifies a healthcare
provider who has completed specialized training in cancer immunotherapy.
The first of
eight modules, presented by Robert Ferris, MD, PhD (Director of the University
of Pittsburgh Medical Center Hillman Cancer Center, long-time SITC member and
past At-Large Director), is now online. It covers basic concepts of immunology, including innate and adaptive immune responses. The other seven module
topics, which will be launched in the weeks ahead, include:
·
Basic
Cancer Immunotherapy Concepts
·
Immune
Checkpoint Blockade
·
Managing
Immune Checkpoint Inhibitor Adverse Events
·
Other Approaches, including Cytokines, Vaccines, Immune
Cell Engagers
·
Oncolytic Viruses and Intralesional Therapy
·
CAR T Cell and Cellular Therapy
·
Implementing Cancer Immunotherapy in Clinical
Practice
SITC executive
leadership, faculty and staff have put many months of effort in the planning
and continued execution of this exciting new SITC program. I would like to
thank all of those involved in the Certificate in Cancer Immunotherapy program,
including Executive Director Tara Withington, CAE, and Past President Howard L.
Kaufman, MD, FACS, both of whom championed this effort and the need for such a
program for multiple years.
To learn more about eligibility requirements to earn your Certificate in Cancer Immunotherapy,
please click here. SITC members receive a 20 percent discount on all Certificate in
Cancer Immunotherapy modules, so if you haven’t yet, please be sure to join the SITC family to
take advantage of this exclusive member benefit.
Mario Sznol, MD
SITC President
No comments:
Post a Comment